J&J Revises Doxil Label To Include Cardiotoxicity Data For Liposomal Agent
This article was originally published in The Pink Sheet Daily
The risk of cardiotoxicity for liposomal doxorubicin is 11% based on a 250-patient breast cancer trial, updated labeling states. Labeling previously said that Doxil's myocardial toxicity would likely be similar to the risk of conventional formulations, which ranges from 6% to 20%.
You may also be interested in...
The U.S. Global AIDS Coordinator's Office suggests it will use its authority to purchase an FDA-approved generic antiretroviral product for which permission could not be obtained from the patent holder. FDA grants tentative approval to a South African firm for a generic co-packaged version of Combivir and Viramune.
Sanofi-Aventis will price its meningococcal conjugate vaccine Menactra in line with Wyeth's pneumococcal vaccine Prevnar
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).